Verona Pharma Re-Works Loan Packages, Boosting Borrowing Capacity, Lowering Expense

MT Newswires Live03-28

Verona Pharma (VRNA) said Friday that it has revised its existing funding agreements by repaying its $100 million revenue interest purchase and sale agreement and increasing its debt facility with funds managed by Oaktree Capital Management and Omers Life Sciences to $450 million on improved terms.

The biopharmaceutical company said it has also borrowed $125 million from an expanded tranche C and reduced the interest rate it pays by 130 basis points to 9.7%.

The company said it can also cut its interest rate to 9.35% by reaching certain sales milestones and it has included a provision that allows it to secure up to $75 million through a working capital revolving credit facility with a separate group of lenders.

Verona Pharma shares were fractionally higher in recent Friday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522572015?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-28 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522572015","market":"sg","top_or_hot":-1,"title":"Verona Pharma Re-Works Loan Packages, Boosting Borrowing Capacity, Lowering Expense","media":"MT Newswires Live","content":"<html><body><p> Verona Pharma (VRNA) said Friday that it has revised its existing funding agreements by repaying its $100 million revenue interest purchase and sale agreement and increasing its debt facility with funds managed by Oaktree Capital Management and Omers Life Sciences to $450 million on improved terms.</p><p>The biopharmaceutical company said it has also borrowed $125 million from an expanded tranche C and reduced the interest rate it pays by 130 basis points to 9.7%.</p><p>The company said it can also cut its interest rate to 9.35% by reaching certain sales milestones and it has included a provision that allows it to secure up to $75 million through a working capital revolving credit facility with a separate group of lenders.</p><p>Verona Pharma shares were fractionally higher in recent Friday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verona Pharma Re-Works Loan Packages, Boosting Borrowing Capacity, Lowering Expense</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerona Pharma Re-Works Loan Packages, Boosting Borrowing Capacity, Lowering Expense\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-28 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Verona Pharma (VRNA) said Friday that it has revised its existing funding agreements by repaying its $100 million revenue interest purchase and sale agreement and increasing its debt facility with funds managed by Oaktree Capital Management and Omers Life Sciences to $450 million on improved terms.</p><p>The biopharmaceutical company said it has also borrowed $125 million from an expanded tranche C and reduced the interest rate it pays by 130 basis points to 9.7%.</p><p>The company said it can also cut its interest rate to 9.35% by reaching certain sales milestones and it has included a provision that allows it to secure up to $75 million through a working capital revolving credit facility with a separate group of lenders.</p><p>Verona Pharma shares were fractionally higher in recent Friday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRNA","symbol_name":"维罗纳制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2522572015","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522572015","pubTimestamp":1743168494,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verona Pharma  said Friday that it has revised its existing funding agreements by repaying its $100 million revenue interest purchase and sale agreement and increasing its debt facility with funds managed by Oaktree Capital Management and Omers Life Sciences to $450 million on improved terms.The biopharmaceutical company said it has also borrowed $125 million from an expanded tranche C and reduced the interest rate it pays by 130 basis points to 9.7%.The company said it can also cut its interest rate to 9.35% by reaching certain sales milestones and it has included a provision that allows it to secure up to $75 million through a working capital revolving credit facility with a separate group of lenders.Verona Pharma shares were fractionally higher in recent Friday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRNA":"维罗纳制药","BK4007":"制药"},"translate_title":"维罗纳制药公司重新制定贷款方案，提高借贷能力，降低费用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRNA":0.9},"content_text":"Verona Pharma (VRNA) said Friday that it has revised its existing funding agreements by repaying its $100 million revenue interest purchase and sale agreement and increasing its debt facility with funds managed by Oaktree Capital Management and Omers Life Sciences to $450 million on improved terms.The biopharmaceutical company said it has also borrowed $125 million from an expanded tranche C and reduced the interest rate it pays by 130 basis points to 9.7%.The company said it can also cut its interest rate to 9.35% by reaching certain sales milestones and it has included a provision that allows it to secure up to $75 million through a working capital revolving credit facility with a separate group of lenders.Verona Pharma shares were fractionally higher in recent Friday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522572015"}